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Abstract
In the present study, we investigated the role of disulfide bridges and sulfhydryl groups in A adenosine receptor2a
 . . X  .binding of the agonist 2-p- 2-carboxyethyl phenylethylamino -5 -N-ethylcarboxamidoadenosine CGS 21680 . To evaluate
w3 xthe presence of essential disulfide bridges, rat striatal membranes were incubated with H CGS 21680 in the presence of
w3 xdithiothreitol and binding of the agonist to membranes was measured. The amount of H CGS 21680 which specifically
bound, decreased progressively upon pretreatment of membranes with increasing concentrations of dithiothreitol. Pretreat-
ment of rat striatal membranes with 12.5 mM dithiothreitol for 15 min at 258C resulted in a 2-fold decrease of A 2a
w3 xadenosine receptor affinity for H CGS 21680, and a reduction in the maximal number of binding sites. The presence of
agonist or antagonist ligands protected the A adenosine receptor sites from the effect of dithiothreitol. We also examined2a
the susceptibility of A adenosine receptors to inactivation by the sulfhydryl alkylating reagent, N-ethylmaleimide. When2a
w3 xrat striatal membranes were pretreated with N-ethylmaleimide for 30 minutes at 378C, a decrease in specific H CGS
21680 binding was observed. Pretreatment of membranes with 1 mM N-ethylmaleimide also resulted in a 2-fold reduction
w3 xof A adenosine receptor affinity for H CGS 21680, as well as a slight decrease in the maximal number of binding sites.2a
Neither agonist nor antagonist ligands were effective in protecting the receptor sites from inactivation by N-ethylmaleimide.
X  . XIn contrast, addition of 100 mM guanosine-5 -O- 3-thiotriphosphate or 5 -guanylylimidodiphosphate were both effective in
protecting the receptor sites from inactivation by N-ethylmaleimide. This protective effect was significant but not complete.
Our data suggest that disulfide bridges play a role in the stuctural integrity of the A adenosine receptor, furthermore,2a
reduced sulfhydryl groups appear to be important but we do not yet know if they are on the receptor or on the G subunit.s a
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1. Introduction
Adenosine modulates a variety of physiological
functions both in the central and peripheral nervous
system via the activation of cell surface receptors
w x1,2 . Pharmacological studies and molecular cloning
techniques have allowed the identification of four
w xadenosine receptor subtypes, termed A 3–6 , A1 2a
w x w x w x7–9 , A 10,11 and A 12–14 . These subtypes,2b 3
expressed either in native tissues or through recombi-
nant techniques in mammalian cell lines, are distin-
guished by their binding affinities for various agonist
and antagonist ligands. To date, all adenosine recep-
tors thus far sequenced, belong to a superfamily of
heptahelical transmembrane receptors which are cou-
pled to a guanine nucleotide-binding regulatory pro-
 .tein G protein . G-protein-coupled receptors elicit
cellular responses via the activation or inhibition of
w xdistinct signaling pathways. Whereas, A 15,16 and1
w xA 17 adenosine receptors are coupled to G pro-3 i
teins, A and A adenosine receptors activate the2a 2b
adenylyl cyclase system through an interaction with
w xG 18 . Similar to other G-protein-coupled receptors,s
adenosine receptors have the characteristic secondary
structure of seven a-helical membrane spanning do-
mains connected by three extra and three intracellular
loops, respectively.
On the basis of conformational characteristics of
ligands and the involvement of histidine residues in
agonist and antagonist bindings as deduced by chemi-
w xcal modification and mutagenesis studies 6,19–21 ,
w x w xthree-dimensional models of A 22,23 , A 23,24 ,1 2a
w xand A 25,26 adenosine receptors have been con-3
structed using the atomic coordinates of the bacterial
protein bacteriorhodopsin. The three-dimensional
model structure of the A adenosine receptor indi-2a
cates that besides two histidine residues located in
helical domains VI and VII, various hydrophilic and
hydrophobic residues are important in accommodat-
ing the agonist ligands. In particular, the hydrophobic
C -substituents of selective A agonists e.g., 2-p-2 2a
 . . X2-carboxyethyl phenylethylamino -5 -N-ethylcarbox-
 . w   wamidoadenosine CGS 21680 and 2 4- 2- 2- 4-
. xaminophenyl methylcarbonylamino ethylamino-
4 . x Xcarbonyl ethyl phenyl ethylamino-5 -N-ethylcarboxa-
 ..midoadenosine PAPA-APEC would fit in the
lipophilic environment, created by Ile132, Phe177, and
249 w xCys on the A receptor 24 . A favorable interac-2a
tion of the carboxyl-terminus of CGS 21680 with
Cys249 of the A receptor has also been suggested2a
w x24 .
That Cys residues are important to ligand binding
w xis supported by experimental data 21 indicating that
the treatment of rabbit striatal membranes with an
A -selective site-directed affinity label, m-phenylen-2a
w .ediisothiocyanate-2- 2-aminoethylamino car-
x Xbonylethylphenylethylamino -5 -N-ethylcarboxamido-
 .adenosine m-DITC-APEC , decreases specific bind-
w3 x w3 xing of H CGS 21680 and H xanthine amine con-
 w wwww . .x xgener 8- 4- 2-aminoethyl amino carbonyl meth-
x x x . w3 x .yl oxy phenyl -1,3-dipropylxanthine H XAC . Se-
quence analysis of A adenosine receptors from2a
various species has shown that this receptor subtype
w xis particularly rich in cysteine residues 27 . An ex-
ample is the rat A receptor which contains thirteen2a
cysteine residues, six within the transmembrane span-
w xning regions and seven in the extracellular loops 24 .
w xJacobson et al. 27 suggested the extracellular cys-
teine residues were involved in the formation of
disulfide bridges that stabilize the receptor structure.
Additionally, the existence of intramolecular disulfide
bridges in rabbit A adenosine receptors has been2a
shown by the ability of reducing reagents to inhibit
w3 x w xH XAC binding to striatal membranes 21 .
G protein-coupled receptors have two highly con-
served cysteine residues in the second and third
w xextracellular loops 28 . In the b -adrenergic recep-2
tor, substitution of either of these cysteine residues
w xwith Val 29,30 by site directed mutagenesis resulted
in a destabilization of the tertiary structure and alter-
ations in the binding characteristics, suggesting the
cysteine residues play a role in maintaining the active
conformation of the receptor. However, data from a
series of b -adrenergic receptor mutants in which the2
cysteines were substituted with Ala show that there is
no disulfide bridge between the two conserved cys-
w xteines 31 . Using reconstituted phospholipid vesicles
which contained purified b -adrenergic receptors and1
w xmammalian G , Pedersen and Ross 32 showed thats
 .treatment of vesicles with dithiothreitol DTT in-
X  .creases the rate of guanosine 5 -O- 3-thiotriphosphate
 .GTPg S binding to G , in both the presence ands
absence of b-adrenergic agonists. DTT appeared to
be working on the b -adrenergic receptor itself, not1
w xon G 32,33 , and it was suggested that DTT acti-s
vates the b -adrenergic receptor by reducing disul-1
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fide bridges to free sulfhydryl groups. Furthermore,
 .the sufhydryl reagent N-ethylmaleimide NEM
causes an irreversible inactivation of DTT-reduced
b -adrenergic receptors, although it has no inhibitory1
effect on the regulatory or ligand binding activities of
w xthe nonreduced receptor 34 .
As rat A adenosine receptors contain numerous2a
cysteine residues in the extracellular and transmem-
brane domains, modification of their redox status
may be an important mechanism for receptor activa-
tion and regulation. In the present study, we investi-
gated the role of the cysteine residues in agonist
binding. The presence of disulfide bridges was stud-
ied by treating rat striatal membranes with DTT and
examining agonist binding. Treatment with DTT re-
sulted in a 2-fold decrease of receptor affinity for the
w3 xagonist, H CGS 21680, and a modest reduction in
the maximal number of binding sites. Binding activ-
ity was protected when rat striatal membranes were
exposed to DTT in the presence of agonist or antago-
nist ligands. Moreover the A adenosine receptors2a
from rat striatal membranes were sensitive to the
thiol-alkylating reagent, NEM. Following treatment
with NEM a decrease in the receptor affinity for
agonists was observed, and the presence of agonist or
antagonist ligands did not protect the receptor bind-
ing activity.
2. Materials and methods
w3 x  .H CGS 21680 41.2 Cirmmol was obtained
from Dupont-New England Nuclear Boston, MA,
. XUSA . Adenosine deaminase, 5 -N-ethylcarboxami-
 .doadenosine NECA and NEM were purchased from
 .Sigma St. Louis, MO, USA . Guanine nucleotides
 X  .guanosine 5 -O-diphosphate GDP and guanosine
X  ..5 -O-monophosphate GMP and nonhydrolyzable
X  .analogs, guanosine 5 -O- 3-thiotriphosphate
 . X GTPg S and 5 -guanylylimidodiphosphate Gpp-
 . .NH p , were purchased from Boeringher-Mannheim
 .Mannheim, Germany . CGS 21680 and XAC were
obtained from Research Biochemicals Natick, MA,
. USA . DTT was purchased from Calbiochem La
.Jolla, CA, USA . Other agents and reagents were
from standard commercial sources.
2.1. Membrane preparation
Striatal tissue was isolated by dissection from male
Sprague-Dawley rat brains. Membranes were pre-
w xpared essentially as previously described 35 . Briefly,
striatal tissue was homogenized in 20 vol ice-cold
 .buffer A 50 mM Tris-HCl pH 7.4, 1 mM EDTA
containing protease inhibitors 20 mgrml soybean
trypsin inhibitor, 200 mgrml bacitracin, and 160
.mgrml benzamidine . The membrane homogenate
was centrifuged at 48 000=g for 10 min at 48C. The
resulting pellet was resuspended in ice-cold buffer B
50 mM Tris-HCl pH 7.4, 1 mM EDTA, 10 mM
.  .MgCl containing protease inhibitors as above and2
 .adenosine deaminase 2 IUrml to 50 mgrml of
original tissue weight, and the suspension was incu-
bated at 378C for 30 min. The membrane homogenate
was recentrifuged and the final pellet was stored in
aliquots at y808C until the time of assay.
2.2. Membrane treatment with DTT
Striatal membranes were resuspended 1.5 mgrml
.of membrane proteins in buffer B and incubated
 .with various concentrations of DTT 0 to 200 mM at
258C for 15 min. The reaction mixtures were then
transferred to 1.5 ml microfuge tubes and centrifuged
 .13 000=g for 4 min at 48C. The resulting pellets
were resuspended in buffer B and recentrifuged for 4
min. This washing step was repeated twice. Adeno-
 .sine deaminase 2 IUrml was present throughout the
entire incubation period and washing steps. The final
pellets were resuspended in buffer B containing
 .adenosine deaminase 2 IUrml at a protein concen-
tration of 1 mgrml and used in the binding assays.
To evaluate the time course of ligand-binding site
inactivation membrane suspensions were incubated
with 12.5 mM DTT at 258C for various times. For
saturation and inhibition experiments, membrane sus-
pensions were incubated with and without 12.5 mM
DTT at 258C for 15 min. The effect of agonists,
antagonists, or guanine nucleotides on ligand binding
site inactivation was evaluated by incubating mem-
brane suspensions with and without these agents for
10 min at room temperature before the addition of
 .DTT 12.5 mM final concentration .
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2.3. Membrane treatment with NEM
Striatal membranes were resuspended 1.5 mgrml
.  .of membrane proteins in buffer B pH 7.7 and
incubated with increasing concentrations of NEM
 .0.5 to 25 mM at 378C for 30 min. At the end of the
incubation the reactions were quenched by the addi-
 .tion of cysteine 10 mM final concentration and the
samples were centrifuged as described above. The
final pellets were resuspended as described above and
used in the binding assays.
In order to assess the time course of ligand-binding
site inactivation, membrane suspensions were incu-
bated with 1 mM NEM at 378C for various times. For
saturation experiments, membrane suspensions were
incubated with and without 1 mM NEM at 378C for
30 min. The effect of agonists, antagonists, or gua-
nine nucleotides on ligand-binding site inactivation
was evaluated by incubating membrane suspensions
with and without these agents for 10 min at room
temperature before the addition of NEM 1 mM final
.concentration .
2.4. Radioligand binding assay
Routine binding assays were performed as previ-
w xously described 36 . Briefly, incubation was for 90
min at 258C in glass tubes containing 0.5 ml of buffer
 . w3 xB with striatal membranes 100 mg , 5 nM H CGS
 .21680, and adenosine deaminase 2 IUrml . Binding
reactions were terminated by filtration through What-
man GFrC filters under reduced pressure. Non spe-
cific binding was defined in the presence of 100 mM
NECA.
For saturation studies, control membranes or mem-
branes treated with chemical reagents 50 mg of
.proteins were incubated in buffer B with 6–8 differ-
w3 xent concentrations of H CGS 21680 ranging from 1
to 90 nM. Competition studies were carried out by
incubating control membranes and membranes treated
w3 xwith 12.5 mM DTT, in buffer B with 5 nM H CGS
21680 and up to 6–8 concentration NECA ranging
from 1 nM to 1 mM. For studying the effect of
w3 xGTPg S on H CGS 21680 binding to control and
 .DTT 12.5 mM treated membranes, 6–8 different
concentrations of the nucleotide were added to the
w3 x incubation buffer together with H CGS 21680 5
.nM . Protein concentrations were determined by the
w xmethod of Lowry et al. 37 , using bovine serum
albumin as standard.
2.5. Data analysis
A non-linear multipurpose curve-fitting computer
 . w xprogram EBDA-LIGAND, Elsevier-Biosoft 38 was
used for analysis of binding data. A partial F test was
used to determine if the binding data were best fit by
a one- or two-site model. Saturation and displacement
curves were also analyzed by computer program
GRAFIT Version 3.0 Erithacus Software, Staines,
. UK and GraphPad Prism Graph Pad Software, San
.Diego, CA, USA . The IC values were converted to50
w xK values by the Cheng and Prusoff equation 39 .i
The statistical significance of the differences between
control and treated groups was evaluated by paired t
 .test Student’s t-test using the Instat computer pro-
 .gram Erithacus Software, Staines, UK .
3. Results
The effects of DTT, a disulfide-reactive reagent,
on agonist binding to rat A adenosine receptors was2a
examined. Rat striatal membranes, prepared as de-
scribed in Section 2, were preincubated with millimo-
lar concentrations of DTT and washed before radioli-
gand binding. The amount of specifically bound
w3 xH CGS 21680 decreased progressively upon pre-
treatment of the membranes with increasing concen-
 .trations of DTT Fig. 1A . The IC value was50
calculated to be 12.5 mM. The binding was nearly
completely abolished by pretreatment of the mem-
branes with 200 mM DTT for 15 min at 258C. Under
w3 xthese conditions, the nonspecific binding of H CGS
21680 was not affected. The effect of DTT was
 .time-dependent Fig. 1B . The inhibition of specific
w3 xH CGS 21680 binding increased for 25 min of
preincubation, while the maximal effect was reached
at 90 min. When the percent of residual binding was
 .plotted on a logarithmic scale Fig. 1B, inset , the
decrease was not linearly related to the preincubation
time. The biphasic nature of the plot suggested that at
least two disulfide bridges were reduced by DTT.
In order to determine whether preincubation with
DTT modified the affinity andror the maximal num-
ber of A binding sites for agonist, we performed2a
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 .  .  .Fig. 1. Inactivation of A adenosine receptors as a function of the concentration of DTT A and incubation time B . A Membranes2a
 .were preincubated with increasing concentrations of DTT 1 to 200 mM for 15 min at 258C, washed three times with buffer, and
w3 xincubated with 5 nM H CGS 21680 as described in Section 2. Specific binding is presented as a function of the concentration of DTT
 .during the preincubation. Control binding 240 fmolrmg protein refers to binding of tracer to membranes pretreated with only buffer B.
 .B Membranes were preincubated with 12.5 mM DTT for different periods of time at 258C, washed three times with buffer, and
w3 xincubated with 5 nM H CGS 21680 as described. Specific binding is presented as a function of the preincubation time. Control binding
refers to binding of tracer to membranes pretreated with only buffer B for each indicated time. Data points are the mean of triplicate
determinations with S.E. less than 10%. These results are representative of experiments conducted two additional times.
w3 xsaturation experiments of H CGS 21680 binding
using control and treated membranes. Specific bind-
w3 xing of H CGS 21680 to control and DTT treated
 .membranes was saturable Fig. 2, left panel . Analy-
sis of binding data using a nonlinear curve-fitting
 .computer program EBDArLIGAND revealed that
the best fit obtained was for a one-site model under
 .both experimental conditions Fig. 2, right panel .
w3 xThe K value for H CGS 21680 binding to ratd
striatal A adenosine receptors in control mem-2a
branes was determined to be 11.7"1.2 nM, while
 .the maximal number of binding sites B wasmax
818"96 fmolrmg of protein. When 12.5 mM DTT
was present during preincubation, analysis of binding
 .  . w3 xFig. 2. Saturation curves left panel and derived Scatchard plots right panel of H CGS 21680 binding to A adenosine receptors in2a
w3 xnative and DTT-treated membranes. Membranes were incubated with increasing concentrations of H CGS 21680 ranging from 0.5 to 90
 .nM. Saturation binding data were transformed using the EBDArLIGAND and GRAFIT Version 3.0 computer programs. ‘ Native
 .membranes, preincubated in buffer B for 15 min at 258C and washed; v membranes pretreated with 12.5 mM DTT for 15 min at 258C
and washed three times with buffer as described under Section 2. For native membranes, the K and B values were 9.2 nM and 917d max
fmolrmg protein, while for treated membranes the K and B values were 18.8 nM and 590 fmolrmg protein. Each point representsd max
the mean of duplicate determinations. These results are representative of experiments conducted three additional times.
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 .data Fig. 2 indicated that the maximal number of
binding sites and the affinity for the radioligand were
diminished with K and B of 18.4"0.5 nM andd max
451"88 fmolrmg protein, respectively. The decline
in the maximal number of binding sites showed no
statistical significance, while the difference among
 .K values was significant P-0.05 .d
w3 xWe also examined the displacement of H CGS
21680 by NECA using membranes preincubated with
either buffer or buffer containing 12.5 mM DTT.
Preincubation of membranes with DTT resulted in a
shift to the right of the displacement curve without
 .changing the shape data not shown . Non-linear
regression analysis of GRAFIT Version 3.0 and
GraphPad Prism computer programs were used to fit
the dose-response curves and derive IC values.50
Both displacement curves showed slope values close
to 1 and the best fits observed were for one-site
 .models GraphPad Prism computer program . For
control membranes a K value of 17.3 nM wasi
obtained, while after DTT treatment the K valuei
was 44.2 nM, indicating a decrease of receptor affin-
ity for NECA by approximately 2.5-fold.
Binding of agonist to A adenosine receptors in2a
rat striatal membranes is modulated by guanine nu-
w xcleoside diphosphate and triphosphate 35,36 . To
assess whether the treatment with DTT affected re-
ceptor G protein coupling, we investigated the inhi-s
bition of agonist binding by GTPg S using mem-
branes treated either with buffer or buffer containing
12.5 mM DTT. The guanine nucleotide inhibited
w3 xspecific H CGS 21680 binding to both types of
membranes in a dose-dependent manner. Both dose-
 .response curves appeared to be biphasic Fig. 3 . For
control membranes a similar result was noted in a
w xprevious study 35,36 . By using non-linear regres-
 .sion analysis GraphPad Prism Version 2.1 of the
inhibition data it was revealed that two receptor
populations with different sensitivity to modulation
by GTPg S binding to G proteins could be identifieds
 .in control and treated membranes Fig. 3 .
In order to determine whether the effect of DTT
was prevented by specific agonist and antagonist
 .  .ligands, either NECA 780 nM or XAC 2.9 mM
were added to the preincubation medium. Protection
experiments were carried out using 12.5 mM DTT. In
the absence of any agonist or antagonist, this concen-
tration of DTT was determined to decrease the num-
w3 x ber of H CGS 21680 binding sites by 50% see Fig.
.1A . Under these conditions, both NECA and XAC
were effective at preserving specific binding of
w3 x  .H CGS 21680 to rat striatal membranes Fig. 4 .
This protective effect was statistically significant but
 .not complete 40% for NECA and 64% for XAC .
These findings indicated that DTT inhibition was
occurring either at the ligand binding site or at a site
that was closely coupled conformationally to the
ligand-binding event.
 .The effect of GTPg S 100 mM on inactivation of
w3 xH CGS 21680 binding sites by treatment with 12.5
mM DTT was also investigated. Both in the absence
and presence of 780 nM NECA, the guanine nu-
cleotide did not show any significant protective effect
 .Fig. 4 . However, the presence of both NECA and
w3 xGTPg S increased the inactivation of H CGS 21680
binding sites by DTT.
In addition to DTT, we also examined the suscep-
tibility of A adenosine receptors to inactivation by2a
the sulfhydryl alkylating reagent, NEM. Pretreatment
of rat striatal membranes with NEM for 30 min at
 .378C resulted in a decrease Fig. 5A of specific
w3 xFig. 3. Effect of GTPg S on H CGS 21680 binding to A 2a
adenosine receptor in native and DTT-treated membranes. Mem-
branes were preincubated in buffer B with and without 12.5 mM
DTT for 15 min at 258C. For binding assays, aliquots of mem-
 . w3 xbranes were incubated in buffer B see Section 2 with H CGS
 .21680 5 nM and increasing concentrations of GTPg S. A non-
linear regression analysis of GraphPad Prism computer program
was used to fit the dose-response curve and derive IC values.50
 .For native membranes B , IC values were: 18.2 nM and 37.250
 .mM. For DTT-treated membranes ’ , IC values were: 24.250
nM and 21.6 mM. Data points are the mean of triplicate determi-
nations with S.E. less than 10%.
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w3 xFig. 4. Inhibition of H CGS 21680 binding to A adenosine receptors by DTT and effects of ligands and guanine nucleotide.2a
Membranes were preincubated with 12.5 mM DTT in buffer B for 15 min at 258C in the presence and absence of the following
compounds: 780 nM NECA; 2.9 mM XAC; 100 mM GTPg S; 780 nM NECAq100 mM GTPg S. Controls were similarly preincubated
w3 x  .in either buffer B or buffer B containing compounds but without DTT. Specific binding of H CGS 21680 5 nM is expressed as percent
of controls. The values are the means"S.E. of 4 to 6 separate experiments performed in duplicate. ) P-0.05: difference between
values of DTTy and DTT plus compound-treated membranes is statistically significant, paired t-test.
w3 xH CGS 21680 binding. An inhibition of 40–50%
was obtained at a NEM concentration of 1 mM.
w3 xSpecific H CGS 21680 binding never dropped be-
low a certain level even when higher concentrations
of NEM were used. When the pretreatment of mem-
branes was performed with 1 mM NEM at 378C at
 .  .  .Fig. 5. Inactivation of A adenosine receptors as a function of NEM concentration A and incubation time B . A Membranes were2a
 .preincubated with increasing concentrations of NEM 0.5 to 25 mM for 30 min at 378C, washed three times with buffer, and incubated
w3 xwith 5 nM H CGS 21680 as described in Section 2. Specific binding is presented as a function of the concentration of NEM during the
 .  .preincubation. Control binding 215 fmolrmg protein refers to binding of tracer to membranes pretreated with only buffer B. B
Membranes were preincubated with 1 mM NEM for different periods of time at 258C, washed three times with buffer, and incubated with
w3 x5 nM H CGS 21680 as described. Specific binding is presented as a function of the preincubation time. Control binding refers to
binding of tracer to membranes pretreated with only buffer B for the indicated time. Data points are the mean of triplicate determinations
with S.E. less than 10%. These results are representative of experiments conducted two additional times.
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different time points, the binding activity decreased
 .rapidly with increase in time Fig. 5B . The maximal
w3 xinhibition of specific H CGS 21680 binding was
reached after 20 min of preincubation, and remained
stable for 90 min. Pretreatment of rat striatal mem-
branes with 12.5 mM DTT at 258C for 25 min
followed by incubation with 1 mM NEM at 378C for
30 min increased the inhibition of specific binding by
 .40–50% data not shown . The result indicated that a
new pool of reduced sulfhydryl groups was available
for NEM alkylation after treatment of membranes
with DTT.
To assess whether pretreatment with NEM leads to
a decrease of the number of binding sites andror
w3 xtheir affinity for H CGS 21680, rat striatal mem-
branes were preincubated in either the presence or
absence of 1 mM NEM at 378C, washed, and then
incubated with increasing concentrations of the radio-
w3 xligand. Specific binding of H CGS 21680 to control
and treated membranes was saturable Fig. 6, left
.panel . Analysis of binding data using a non-linear
 .curve fitting computer program EBDArLIGAND
 .resulted in linear plots Fig. 6, right panel , indicating
the existence of a single class of binding sites in
control and NEM treated membranes. However, pre-
treatment with NEM resulted in a decrease in the
number of receptor sites and of their affinity for the
radioligand. For control membranes, the derived Kd
and B values were 15.0"1.67 nM and 719"13max
fmolrmg protein, whereas for NEM treated mem-
branes the K and B values were determined tod max
be 33.6"5.8 nM and 570"32 fmolrmg protein,
respectively. Statistical analysis showed that the ob-
served differences among K or B values wered max
not significant.
The influence of agonists, antagonists and guanine
nucleotides on A adenosine receptors NEM medi-2a
ated inactivation was examined. Addition of agonist,
 .  .either NECA 780 nM or CGS 21680 780 nM
before preincubation of membranes with 1 mM NEM
did not protect the receptor sites from inactivation
 .  .Fig. 7, left panel . The antagonist, XAC 2.9 mM ,
was also ineffective in protecting the receptor sites
 ..Fig. 7, left panel . These results suggested that
alkylation occurred at cysteine residues which were
not in close proximity to the active site of the recep-
 .  .tor. The addition of GTPg S 100 mM or Gpp NH p
 .100 mM effectively protected the receptor sites
 .from inactivation Fig. 7, right panel with the protec-
tive effect being significant but not complete 58%
 . .  .for Gpp NH p and 57% for GTPg S . Gpp NH p and
GTPg S prevented inactivation of A adenosine re-2a
ceptors to a similar extent in the presence or absence
 .of NECA Fig. 7, left panel . The degree of protec-
 .tion by Gpp NH p plus NECA and GTPg S plus
NECA was 50% and 58%, respectively. At a concen-
 .  . w3 xFig. 6. Saturation curves left panel and derived Scatchard plots right panel of H CGS 21680 binding to A adenosine receptors in2a
w3 xnative and NEM treated membranes. Membranes were incubated with increasing concentrations of H CGS 21680 ranging from 0.5 to
 .90 nM. Saturation binding data were transformed using the EBDArLIGAND and GRAFIT Version 3.0 computer programs. ‘ Native
 .membranes preincubated in buffer B for 30 min at 378C and washed; v membranes pretreated with 1 mM NEM for 30 min at 378C and
washed three times with buffer as described under Section 2. For native membranes, the K and B values were 13.5 nM and 725d max
fmolrmg protein, while for treated membranes the K and B values were 23.4 nM and 520 fmolrmg protein. Each point representsd max
the mean of duplicate determinations. These results are representative of experiments conducted three additional times.
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w3 xFig. 7. Inhibition of H CGS 21680 binding to A adenosine receptor and effects of ligands and guanine nucleotides. Membranes were2a
 .preincubated with 1 mM NEM in buffer B pH 7.7 for 30 min at 378C in the presence and absence of the following compounds: 780 nM
 .NECA; 780 nM NECAq100 mM GTPg S; 780 nM NECAq100 mM Gpp NH p; 2.9 mM XAC; 780 nM CGS 21680; 100 mM GTPg S;
 .100 mM Gpp NH p; 250 mM GDP. Controls were similarly preincubated in either buffer B or buffer B containing compounds but
w3 x  .without NEM. Specific binding of H CGS 21680 5 nM is expressed as percent of controls. The values are the means"S.E. of 4 to 6
separate experiments performed in duplicate. ) P-0.05, )) P-0.01: difference between values of NEMy and NEM plus compound-
treated membranes is statistically significant, paired t-test.
tration of 250 mM, GDP showed a modest protective
 .  . effect 23% Fig. 7, right panel , while GMP 250
.  .mM was not effective data not shown .
4. Discussion
w xIn the model proposed by Jacobson et al. 27 ,
several disulfide bridges are present in the extracellu-
lar loops of A adenosine receptors. Thus, reducing2a
reagents such as DTT might inactivate the receptor
by opening structurally important disulfide bridges.
Additionally, agonist and antagonist ligands may pro-
duce a conformational change of the receptor so as to
bury one or more disulfide bridges. Alternatively, if
the disulfide bridges are located near the binding sites
of the receptor it is conceivable that binding of the
ligand would shield them from reduction by DTT.
Molecular modeling of the A adenosine receptor2a
w x24 does not implicate the participation of the 7 to 8
cysteine residue located in the extracellular loops in
forming the ligand binding site. However, these mul-
tiple linkages may be important in maintaining nor-
mal function by the receptor, in particular, binding
and activation.
The presence of disulfide bridges between con-
served cysteine residues in the extracellular loops of
G protein coupled receptors has been extensively
investigated. Using site-directed mutagenesis,
rhodopsin, b -adrenergic, and muscarinic acetyl-2
choline receptors have been studied. Biochemical
analysis of rhodopsin indicated that two cysteine
residues are involved in an intramolecular disulfide
bridge that links the second and third extracellular
w xloops of the receptor 40 . Moreover, in experiments
with mutants of rhodopsin in which one or both of
w xthe cysteines were substituted with Ala 41 , findings
were consistent with the presence of a disulfide bridge
between the conserved cysteine residues. The disul-
fide bridge does not appear to be required for binding
of the ligand retinal, but rather for the stability of the
w xactivated intermediate, metarhodopsin II 41 . The
metarhodopsin II state of rhodopsin is equivalent to
the high affinity state of hormone receptors. For the
b -adrenergic receptor the information is less consis-2
tent. Some studies indicate that there are two extra-
w xcellular bridges 29,30 , while other work does not
support the presence of a disulfide bridges between
w xthe two conserved cysteine residues 31 . The thiol
compound DTT has been shown to have a direct
w xeffect on b-adrenergic receptors 42,43 .
Pretreatment of rat striatal membranes with DTT
w3 xcaused a decline of the total number of H CGS
21680 binding sites and a decrease of their affinity
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for the radioligand. Guanine nucleoside triphosphate
still modulated agonist binding to these low-affinity
binding sites in a dose-dependent manner. Binding
activity was partially protected if rat striatal mem-
branes were treated with DTT in the presence of
agonist or antagonist ligands. These results pointed
out that DTT inhibition was occurring either at the
ligand binding site or at a site that was closely
coupled conformationally to the ligand-binding event.
After analyzing chimeric A rA receptors, Olah1 3
w xet al. 25 suggested that the second extracellular loop
of adenosine receptors plays an important role in
agonist and antagonist binding. A cysteine residue
conserved in all adenosine receptor subtypes is in the
second extracellular loop of both bovine A and rat1
A adenosine receptors. This cysteine residue has3
been hypothesized to be involved in disulfide bridge
w xformation in all adenosine receptor subtypes 44 .
However, when rat cortical membranes were preincu-
bated with different concentrations of DTT and bind-
6 w3 xing of a selective agonist N - H cyclohexyladeno-
w3 x .sine H CHA to A adenosine receptors was mea-1
sured, no significant decrease of specific binding was
 .detectable data not shown . The differences between
A and A adenosine receptors indicate that cysteine1 2a
residues in the extracellular loops of adenosine recep-
tor subtypes may play different roles in receptor
stabilization and high affinity agonist binding. Re-
cently, the importance of the extracellular loops in
the binding of ligands to the human A adenosine2a
receptor has been examined through site-directed mu-
w xtagenesis 45 . This study indicated that glutamate
residues in the second extracellular loop were re-
quired for ligand binding. The role of three cysteine
residues present in this same loop has not yet been
investigated. Replacement of a cysteine residue in the
third extracellular loop with a glycine has no effect in
agonist or antagonist binding, suggesting that any
potential disulfide bridge formed with another cys-
teine residue would not be essential for structural
integrity of the receptor. However, this observation
does not exclude formation of disulfide bridges be-
tween cysteine residues in the second extracellular
loop as being important in stabilizing the high affin-
ity state of the receptor for agonist ligands.
In the VI transmembrane domain of the rat A 2a
adenosine receptor, cysteine residues are located at
positions 240 and 249. In the three-dimensional model
w xof the rat A adenosine receptor 24 , the hydropho-2a
bic C2-substituents of selective A agonists are ac-2a
commodated in a lipophilic environment that includes
Cys249. The involvement of a cysteine residue in
ligand binding is supported by experimental data
obtained with a site-directed chemical modification
w xapproach 21 . Studies employing site-directed muta-
w xgenesis of the human b -adrenergic receptor 462
have suggested that a conserved cysteine residue
 285.Cys in the VI transmembrane domain is impor-
tant for agonist mediated activation of adenylyl cy-
clase. In the rat A adenosine receptor, Cys240 might2a
play a similar role. In order to evaluate the impor-
tance of sulfhydryl groups we investigated the effect
of the thiol-alkylating reagent NEM on agonist bind-
ing to rat striatal membranes. Preincubation of mem-
branes with NEM caused a time-dependent decrease
of specific binding. The maximal effect was a 50%
inhibition indicating that a limited number of recep-
tors was sensitive to this treatment. Moreover, NEM
treatment resulted in a 2-fold decrease of receptor
affinity for the radioligand and a modest reduction of
the maximal number of binding sites. Thus, the pres-
ence of free sulfhydryl groups appears to be more
important for high affinity agonist binding than for
receptor stability. Neither agonist nor antagonist lig-
ands were able to prevent the effects of NEM. This
finding indicates that the reactive sulfhydryl groups
modified by the alkylating reagent are not in close
proximity to the receptor binding site or in any other
location that changes conformation upon ligand bind-
ing. Therefore, a site of modification does not appear
to be at Cys249. Additionally, we found that the
nonhydrolyzable analogs of GTP, GTPg S and
 .Gpp NH p, were able to prevent the effect of NEM.
NEM has been shown to modify cysteine residues
w xon pertussis toxin sensitive G proteins 47 , and
similar to pertussis toxin ADP-ribosylated G pro-iro
teins, NEM-treated G proteins cannot be activatediro
w xby receptors 48 . However, it is thought that NEM-
treatment does not uncouple G proteins from recep-s
w xtors 47 . Our findings raise the possibility that the
modified sulfhydryl groups are not present on the
receptor, but rather are on the G subunit. If thesa
reactive sulfhydryl groups are on the A adenosine2a
receptor, binding of a nonhydrolyzable analog of
GTP to the G subunit may have an allosteric effectsa
on receptor conformation such that the reactive cys-
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teine residues are buried and no longer sensitive to
alkylation. Alternatively GTP analogs may directly
protect reactive sulfhydryl groups on the G subunitsa
from alkylation, while irreversible modification of
these same groups by NEM would lock the subunit in
a conformation similar to that induced by guanine
nucleotide binding.
For b -adrenergic receptors in turkey erythrocyte1
membranes, an effect of NEM treatment on ligand
w xbinding has been reported 49,50 . However, b -1
adrenergic receptors were only inactivated when
membranes were exposed to NEM in the presence of
a b-adrenergic agonist. The alkylating reagent had no
effect on the free or antagonist-bound forms of the
receptor, while guanine nucleotides prevented the
w xinactivation 50 , and it was suggested that the reac-
w xtive sulfhydryl groups might reside on G 32,50 .s
Therefore, NEM appears to have similar effects on
two different types of G -coupled receptors. How-s
ever, it should be noted that rat A adenosine recep-2a
tors are sensitive to NEM treatment even in the
absence of agonist ligands. This difference may be
due to the presence of the natural agonist, adenosine,
in our membrane preparation.
In conclusion, our data suggest that disulfide
bridges are important for the structural integrity of
the rat A adenosine receptor and for proper agonist2a
binding. One or more of these disulfide bridges ap-
pear to be located in receptor regions that are closely
coupled conformationally to the ligand binding event.
At present, we cannot discriminate whether the
NEM-alkylated sulfhydryl groups are on the A 2a
adenosine receptor or on the G subunit.sa
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